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Abstract
The effects of intravenous N-acetylcysteine on hepatic and systemic haemodynamics were investigated in 11 patients with stable cirrhosis (eight alcohol; two primary bilary cirrhosis; one cryptogenic). N-acetylcysteine administration had no effect on the mean heart rate or mean arterial blood pressure despite a significant fall in systemic and pulmonary vascular resistance. Cardiac index increased but estimated liver blood flow and portal venous pressure did not change significantly. Administration of N-acetylcysteine resulted in increased oxygen delivery to the tissues because of the increased cardiac index but this was not accompanied by a rise in either arteriovenous oxygen extraction ratio or mean tissue oxygen consumption. Therefore N-acetylcysteine administration seems to confer no haemodynamic benefit to patients with cirrhosis.
(Gut 1994; 35: 1290-1293) N-acetylcysteine (NAC), a sulphurated amino acid, has been reported to increase cardiac output, tissue oxygen delivery, and utilisation in fulminant hepatic failure. ' As some of the haemodynamic changes seen in patients with cirrhosis are similar to those with fulminant hepatic failure, N-acetylcysteine may also increase tissue oxygen use and delivery in patients with cirrhosis. The aim of this study was to determine the haemodynamic effects of this agent in cirrhosis with particular reference to oxygen delivery and consumption. Each patient fasted after a light breakfast on the day of the study. In the catheter laboratory a 7.5 F introducer (Edwards, Critical Care Division, Irvine, USA) was placed in the right femoral vein under local anaesthesia (2% lignocaine). A Swan-Ganz catheter (7 F Edwards, Irvine, USA) was inserted under fluoroscopic screening and continuous pressure recording into the pulmonary artery. The tip of the catheter was positioned in a major branch of the pulmonary artery. The mean heart rate (from ECG monitor, Hewlett Packard HP monitoring system, Germany) and mean arterial blood pressure (manual syphygomomanometer) were checked every five minutes initially until all patients had achieved haemodynamic stability for at least 20 minutes. Simultaneous femoral artery, pulmonary artery, and femoral vein blood gas samples were then taken into heparinised blood gas syringes and analysed immediately for oxygen saturation (Co-Oximeter 282, Instrumentation Laboratory, Lexingham, MA, haemoglobin, and oxygen tension (P02) (ABL 2000, Radiometer, Copenhagen). The pulmonary artery free and wedge pressure and cardiac output (by Swan-Ganz thermodilution method using 10 ml of cold 5% dextrose as injectate) were estimated. The hepatic venous pressure gradient (wedged hepatic venous pressure -free hepatic venous pressure) and estimated liver blood flow (ICG, Cardiogreen Hynson, Westcott and Dunning Inc, Baltimore, MD -continuous infusion method4 5) were measured immediately before and after NAC infusion randomly in six of 11 patients with cirrhosis. For hepatic pressure measurements a sidewinder II catheter (Cordis, USA) was inserted into the main right hepatic vein under fluoroscopic control. Inflating and releasing the balloon permitted repeated consistent measurements of wedge and free hepatic pressure respectively to be made. The intravenous infusion of indocyanine green was made up in saline and infused at a rate of 0.20 mg/m2/min after a priming dose of 0.20 mg/kg body weight. After a 30 minute equilibration period three simultaneous samples of peripheral and hepatic venous blood were drawn into heparinised syringes for the determination of estimated liver blood flow. The indocyanine green concentrations in the serum and infusion fluid were estimated by spectrophotometry at 810 nm in a Zeiss PMQ II spectrophotometer against a blank serum sample. The estimated liver blood flow was derived from the equation estimated liver blood flow=R/(A-H) (1-PCV), where R is the rate of infusion of indocyanine green in mg/min; A and H are the concentrations of dye in peripheral and hepatic venous blood in mg/l; and PCV is the packed cell volume.47
As the systemic haemodynamic effect of NAC has been assessed previously in patients without liver disease it was felt that inclusion of normal healthy controls in an invasive study such as this was unethical.8 9 The haemodynamic response, however, to infusion of the same volume of 5% dextrose as above but not containing N-acetylcysteine to five (randomly selected) patients with cirrhosis was assessed to investigate any potential volume loading effect of the infusion.
STATISTICAL ANALYSIS OF HAEMODYNAMIC VARIABLES
The results after the infusion of NAC were compared with the baseline haemodynamic values before infusion. All results were expressed as mean (SEM) with statistical analysis by a two tailed paired Student's t test.
Results
Administration of N-acetylcysteine had no effect on mean heart rate or arterial blood pressure (Table I) . Infusion of NAC resulted in vasodilatation with a significant reduction in both mean systemic vascular resistance index and pulmonary vascular resistance index (Table I) . No significant changes in right atrial pressure, pulmonary artery free and wedge pressure occurred.
Administration of NAC resulted in a significant increase in mean oxygen delivery resulting from an increase in the mean cardiac index (Table I) . This was associated with a significant increase in left ventricular stroke work index (Table I) . Both arteriovenous oxygen extraction ratio and the mean oxygen consumption did not rise in response to NAC (Table I) .
The effect ofN-acetylcysteine on mean blood gas values showed a minor fall in arterial oxygen tension and increase in venous oxygen tension after NAC administration (Table II) .
There was no significant statistical correlation between Child's score variables -that is, serum albumin, bilirubin, and prothrombin ratio -and degree of change in response to NAC of cardiac index, oxygen delivery, oxygen consumption, oxygen extraction ratio or blood gases.
Mean estimated liver blood flow increased in response to NAC infusion; but did not achieve statistical significance (Table III) . Wedged hepatic venous pressure, free hepatic venous pressure, and portal pressure showed no significant change after N-acetylcysteine infusion (Table III) .
The control group of five patients who received intravenous dextrose alone showed no significant change in haemodynamic parameters (Table IV) .
Discussion
We have shown that NAC acts as a vasodilator in patients with cirrhosis, similar to the effect shown in fulminant hepatic failure.1 This has not occurred in patients with cardiac failure, with symptoms of chest pain or in those fully recovered from acute liver failure. 8 9 NAC is not known to possess direct relaxant activity in normal vascular smooth muscle'0 and given to pigs, both healthy and with septic shock produced no significant haemodynamic changes. '1 12 There is thus convincing evidence that NAC has no haemodynamic action in healthy controls. As NAC given to our 11 cirrhotic patients clearly conferred no haemodynamic benefit we felt that to study more patients would be unethical.
The five patients in our control group showed no vasodilation in response to dextrose infusion alone (Table IV) . Thus the postulate that the haemodynamic changes in the 11 patients given N-acetylcysteine infusion were caused by the effects of volume loading or patients relaxing after the initial invasive procedures can be ruled out.
In patients with cirrhosis, unlike those with fulminant hepatic failure,' the mean arterial pressure did not change and the oxygen extraction ratio and 02 consumption did not rise in response to NAC infusion (Table I) . The cardiac index, systemic vascular resistance index, pulmonary vascular resistance index, stroke work index, and 02 delivery % changes were, however, similar between cirrhotic and fulminant hepatic failure patients ( Table 1) .
As most drugs that primarily cause afterload reduction increase cardiac index without affecting left ventricular stroke work index (or rate pressure product, or other measures of myocardial consumption) the rise in cardiac index in association with left ventricular stroke work index seen here is suggestive of a positive inotropic response rather than purely peripheral vasodilation and reduction in left ventricular afterload.
Interestingly, there were no reported changes in arterial Po2, calculated a-v tension gradient, and shunt in hepatic failure patients in response to NAC.' Errors in estimation of mixed venous 02 saturation and tension could occur if the blood is drawn rapidly or if the catheter is positioned peripherally within the pulmonary artery because of contamination of the mixed venous pulmonary blood with arterialised blood drawn from the pulmonary capillaries and veins. We are confident that sufficient care was taken to prevent this error occurring in our study. This is supported by the increasing P02 trend seen in peripheral vein samples after NAC infusion, parallelling the increase in pulmonary artery P02 after the infusion (Table II) .
We believe that the difference between the action of NAC to increase 02 delivery in cirrhosis but not tissue 02 consumption (compared with fulminant hepatic failure) may be because patients with cirrhosis have established pulmonary shunts'3 and NAC acts as a vasodilator to increase pulmonary shunting. This hypothesis is supported by the finding that pulmonary vascular resistance (Table I) fell in response to NAC infusion. The exact nature of such shunting is controversial. '4-'8 The multiple inert gas elimination technique '9 has also shown V/Q mismatching in some patients with cirrhosis. Patients with lower pulmonary vascular resistance have greater V/Q mismatch.'3 Our data suggest that cirrhotic patients, unlike hepatic failurel and cardiac failure20 patients, are not dependent on supply of oxygen to increase consumption. This may, however, just reflect the well compensated liver disease in most of these patients and it might be necessary to evaluate a group of grade C patients alone before a beneficial effect of NAC can be excluded.
Differences between fulminant hepatic failure patients and our cirrhotic patients may also result from the fact that some of the fulminant patients had encephalopathy (with and without neurohumoral factors) and were on mechanical ventilation (volume controlled) with continuous intravenous infusion of muscle relaxant (atracurium 50 mg/h).' Pulmonary capillary wedge pressure had to be stabilised at [8] [9] [10] [11] [12] [13] [14] N-acetylcysteine given to patients with cirrhosis is probably not of haemodynamic value. This study illustrates that extrapolation of drug use between patients with fulminant hepatic failure and chronic liver disease is not always justifiable. We would still advocate its use, however, in paracetamol poisoning, particularly in patients with chronic alcohol intake (as such patients have increased susceptibility to paracetamol). 25 26 This work has been presented in part at the British Society of Gastroenterology meeting 24-26th March 1993 and appears in abstract form in Gut 1993; 34 (suppl): S43.
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